27349182|t|Beneficial effects of voglibose administration on body weight and lipid metabolism via gastrointestinal bile acid modification
27349182|a|This study was designed with the goal of examining the effects of voglibose administration on body weight and lipid metabolism and underlying mechanism high fat diet -induced obese mice. Male C57BL/6 mice were randomly assigned to one of four groups: a control diet (CTL), high-fat diet (HF), high-fat diet supplemented with voglibose (VO), and high fat diet pair-fed group (PF). After 12 weeks, the following characteristics were investigated: serum lipid and glucose levels, serum polar metabolite profiles, and expression levels of genes involved in lipid and bile acid metabolism. In addition, pyrosequencing was used to analyze the composition of gut microbiota found in feces. Total body weight gain was significantly lower in the VO group than in the CTL, HF, and PF groups. The VO group exhibited improved metabolic profiles including those of blood glucose, triglyceride, and total cholesterol levels. The 12- week voglibose administration decreased the ratio of Firmicutes to Bacteroidetes found in feces. Circulating levels of taurocholic and cholic acid were significantly higher in the VO group than in the HF and CTL groups. Deoxycholic acid levels tended to be higher in the VO group than in the HF group. Voglibose administration downregulated expression levels of CYP8B1 and HNF4α genes and upregulated those of PGC1α, whereas FXRα was not affected. Voglibose administration elicits changes in the composition of the intestinal microbiota and circulating metabolites, which ultimately has systemic effects on body weight and lipid metabolism in mice.
27349182	0	18	Beneficial effects	UnknownType	C0683156
27349182	22	31	voglibose	T109,T121	C0532578
27349182	32	46	administration	T061	C1533734
27349182	50	61	body weight	T032	C0005910
27349182	66	82	lipid metabolism	T044	C0598783
27349182	87	103	gastrointestinal	T022	C0012240
27349182	104	113	bile acid	T109,T123	C0005390
27349182	114	126	modification	UnknownType	C0579005
27349182	132	137	study	T062	C0008972
27349182	160	164	goal	T170	C0018017
27349182	182	189	effects	T169	C0728866
27349182	193	202	voglibose	T109,T121	C0532578
27349182	203	217	administration	T061	C1533734
27349182	221	232	body weight	T032	C0005910
27349182	237	253	lipid metabolism	T044	C0598783
27349182	269	278	mechanism	T169	C0441712
27349182	279	292	high fat diet	T061	C0521974
27349182	302	312	obese mice	T015	C0025933
27349182	314	318	Male	T032	C0086582
27349182	319	331	C57BL/6 mice	T015	C1521751
27349182	370	376	groups	T096	C1642385
27349182	380	392	control diet	T096	C0009932
27349182	394	397	CTL	T096	C0009932
27349182	400	413	high-fat diet	T096	C1642385
27349182	415	417	HF	T096	C1642385
27349182	420	461	high-fat diet supplemented with voglibose	T096	C1642385
27349182	463	465	VO	T096	C1642385
27349182	472	500	high fat diet pair-fed group	T096	C1642385
27349182	502	504	PF	T096	C1642385
27349182	516	521	weeks	T079	C0439230
27349182	537	552	characteristics	T080	C1521970
27349182	572	583	serum lipid	T059	C0428462
27349182	588	602	glucose levels	T034	C0583332
27349182	641	658	expression levels	T081	C3244092
27349182	662	667	genes	T028	C0017337
27349182	680	685	lipid	T044	C0598783
27349182	690	710	bile acid metabolism	T044	C0678714
27349182	725	739	pyrosequencing	T059	C2732543
27349182	764	775	composition	T201	C0486616
27349182	779	793	gut microbiota	T001	C2985398
27349182	803	808	feces	T031	C0015733
27349182	810	832	Total body weight gain	T033	C0043094
27349182	837	856	significantly lower	T081	C4055638
27349182	864	872	VO group	T096	C1642385
27349182	885	888	CTL	T096	C0009932
27349182	890	892	HF	T096	C1642385
27349182	898	907	PF groups	T096	C1642385
27349182	913	921	VO group	T096	C1642385
27349182	941	959	metabolic profiles	T039	C3853758
27349182	979	992	blood glucose	T059	C0392201
27349182	994	1006	triglyceride	T034	C0428475
27349182	1012	1036	total cholesterol levels	T034	C0428466
27349182	1046	1050	week	T079	C0439230
27349182	1051	1060	voglibose	T109,T121	C0532578
27349182	1061	1075	administration	T061	C1533734
27349182	1099	1109	Firmicutes	T007	C1254144
27349182	1113	1126	Bacteroidetes	T007	C0995456
27349182	1136	1141	feces	T031	C0015733
27349182	1155	1161	levels	T080	C0441889
27349182	1165	1176	taurocholic	T109,T121,T123	C0039358
27349182	1181	1192	cholic acid	T109,T121,T123	C0055568
27349182	1198	1218	significantly higher	T081	C4055637
27349182	1226	1234	VO group	T096	C1642385
27349182	1247	1249	HF	T096	C1642385
27349182	1254	1264	CTL groups	T096	C0009932
27349182	1266	1282	Deoxycholic acid	T109,T121,T123	C0011479
27349182	1283	1289	levels	T080	C0441889
27349182	1317	1325	VO group	T096	C1642385
27349182	1338	1346	HF group	T096	C1642385
27349182	1348	1357	Voglibose	T109,T121	C0532578
27349182	1358	1372	administration	T061	C1533734
27349182	1373	1386	downregulated	T044	C0013081
27349182	1387	1404	expression levels	T081	C3244092
27349182	1408	1414	CYP8B1	T028	C1413895
27349182	1419	1430	HNF4α genes	T028	C1415629
27349182	1435	1446	upregulated	T044	C0041904
27349182	1456	1461	PGC1α	T028	C1418779
27349182	1471	1475	FXRα	T028	C1417825
27349182	1494	1503	Voglibose	T109,T121	C0532578
27349182	1504	1518	administration	T061	C1533734
27349182	1542	1553	composition	T201	C0486616
27349182	1561	1582	intestinal microbiota	T001	C2985398
27349182	1587	1610	circulating metabolites	T123	C0870883
27349182	1633	1649	systemic effects	UnknownType	C0678788
27349182	1653	1664	body weight	T032	C0005910
27349182	1669	1685	lipid metabolism	T044	C0598783
27349182	1689	1693	mice	T015	C0025929